Navigation Links
Kosan Announces Data Presentations at ASCO 2008 Annual Meeting
Date:5/14/2008

HAYWARD, Calif., May 14 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) today announced that updated data will be presented on tanespimycin, the company's lead Hsp90 inhibitor, from a Phase 2 trial in combination with Herceptin(R) in patients with HER2-positive metastatic breast cancer, at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO), being held at McCormick Place, Chicago, IL, May 31 through June 3, 2008.

Abstract 1027, titled, "Phase 2 trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC)," will be presented in a poster session in room E450a on Tuesday, June 3, 2008 from 8:00 am through 12:00 noon CT. The presenter is Shanu Modi, M.D., of Memorial Sloan-Kettering Cancer Center. This abstract will be highlighted in a poster discussion session to be held from 11:00 am - 12:00 noon CT in room E450b.

In addition, data from a Phase 1 trial of Kosan's Hsp90 inhibitor, alvespimycin, will be presented in an oral session on Monday, June 2, 2008 at 8:00 am to 11 am CT. Abstract 2502, titled, "First use of an oral Hsp90 inhibitor in patients (Pts) with solid tumors: Alvespimycin (A) administered QOD or QD," will be presented at 8:00 to 8:15 am CT in room W375a by Keith Flaherty, M.D., of the University of Pennsylvania.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development: Hsp90 (heat shock protein 90) inhibitors and epothilones. Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with V
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
2. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
3. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
6. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
7. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
8. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
9. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... Bio Co., Ltd, ( www.rnl.co.kr ) a leading ... announced today that a 46-year-old female, Kang Sook ... cell treatment. Park was suffering from MS (Multiple ... nervous system (brain and spinal cord). ,, ... nerves of the central nervous system degenerate. MS ...
(Date:12/4/2009)... A simple, inexpensive computer tool that measures volume changes ... picked up by a CT scanner can rule out ... to diagnose true cancers with fewer, less expensive and ... The new diagnostic guidelines are described in a paper ...
(Date:12/4/2009)... Dec. 4 Thermographic Diagnostic Imaging (TDI), part ... New Jersey continues to provide superior quality infrared ... TMJ and sinus regions to assist in the ... ,, Thermography utilizes infrared imaging cameras that ...
Breaking Medicine Technology:Multiple Sclerosis Patient Finds Hope Through Stem Cell Treatment 2European Lung Cancer Screening Trial Demonstrates New Inexpensive Strategy for Improving Accuracy of Diagnosis 2Discover Health Through Awareness 2Discover Health Through Awareness 3Schizophrenia Drug Got Bad Rap 51447 1Schizophrenia Drug Got Bad Rap 51447 2New White Paper from The Beryl Institute Provides Insights to Generations 51445 1InteKrin Therapeutics Announces Appointment of Geoffrey M Parker as Chief Business Officer 51443 1InteKrin Therapeutics Announces Appointment of Geoffrey M Parker as Chief Business Officer 51443 2
(Date:12/6/2009)... A new study provides welcome news for patients ... (VTE). , The condition is estimated to impact ... when an abnormal clot forms in a vein and ... In some cases, the clot may detach from its ... the lungs, causing a potentially fatal condition known as ...
(Date:12/5/2009)... in a phase 1/2 clinical trial that it ... patients newly diagnosed with multiple myeloma, a cancer of ... Dana-Farber Cancer Institute. , Partial responses or better were ... the drug combination in the multi-center study, with 74 ... the phase 2 population, reports Paul G. Richardson, MD, ...
(Date:12/5/2009)... This Type of Blood Cancer Is Most Challenging-- ... Pediatric oncologists have identified specific genes, dubbed partner genes, ... form of leukemia in infants. By more accurately defining ... infants may benefit from particular treatments. ,, Oncologists ...
(Date:12/5/2009)... Technology Center helps companies develop and test their cleaning processes. The ... variety of industries and solve problems for customers relating to cleaning ... ... 5, 2009 -- Midbrook, Inc , a Jackson, MI-based company, ...
(Date:12/4/2009)... Varian Medical Systems (NYSE: VAR ) announced ... 2010 Annual Meeting of Stockholders for February 11, 2010 with ... be held at the Crowne Plaza Cabana Hotel, 4290 El ... The meeting will be webcast by Thomson Financial and can ...
Breaking Medicine News(10 mins):Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2
... - Exhibits Growth In All Existing Markets -, ... Bulletin Board: PMQC, PMQCU, PMQCW), the third largest long-term ... served. The,Company experienced growth across all four of its ... in the New York City,metropolitan area, as well as ...
... HCA Inc. announced,today that it had commenced a ... aggregate principal amount of its outstanding debt. The series,of ... offer (the "Notes"),are listed in the table below with ... conditions of the tender offer are described in an,Offer ...
... novel drug designed to lessen muscle damage from a heart ... Research Institute. Results of the study, available online and to ... Circulation, reflect the first time the drug has been tested ... the activity of an enzyme called delta protein kinase C ...
... CHAPEL HILL, N.C., Feb. 7 Selecting and ... a new,challenge for marketing leaders at pharmas and ... share similar,structure, composition, and responsibilities -- all detailed ... Best Practices, LLC., According to research findings, ...
... on Exercise (ACE) Research Proves Dance Dance ... Revolution (DDR) Can Be a Tremendous Workout, SAN DIEGO, ... that eliminate conventional hand controllers in favor of more,full-body interaction, ... to the test., The ACE commissioned research out of ...
... Brings Leading Clean Indoor Air and Health Advocates Together ... Indoor Air Quality, SOUTHBOROUGH, Mass., Feb. 7 Most ... did you know the Environmental,Protection Agency says levels of indoor ... occasionally even 100 times higher -- than outdoor air,pollution levels? ...
Other Medicine News:Health News:Chem Rx Surpasses 65,000 Residents Served 2Health News:HCA Announces Cash Debt Tender Offer 2Health News:HCA Announces Cash Debt Tender Offer 3Health News:HCA Announces Cash Debt Tender Offer 4Health News:HCA Announces Cash Debt Tender Offer 5Health News:HCA Announces Cash Debt Tender Offer 6Health News:Novel compound may lessen heart attack damage 2Health News:Pharmaceutical Product Commercialization & Governance Best Practices: Securing Talent for Highly-Effective Brand Teams 2Health News:Can a Video Game Make Your Kids More Fit? 2Health News:February is Designated as 'National Care About Your Indoor Air' Month 2Health News:February is Designated as 'National Care About Your Indoor Air' Month 3Health News:February is Designated as 'National Care About Your Indoor Air' Month 4
Double bent ends prevent wire from catching when pushed forward. Designed for use with the Castroviejo Snare (E3675). Package of 12 stainless steel wires. Overall length 4.3 inches....
Replacement snares for the E3525. 3 per package....
... with the E3671 twisted snare wires. The wire ... and the loop can be stopped at any ... the loop can be slipped down the nerve ... inches. Comes with one package of E3671 twisted ...
Open ring design for globe fixation during various ocular procedures. Blunt fixation points. Swivel handle provides increased flexibility. Manufactured in titanium....
Medicine Products: